002349.SZ
Jinghua Pharmaceutical Group Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 6.81
−1.59%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 1.5B | 1.4B | 1.5B | 1.6B |
| Cost of Revenue | 696.7M | 702.4M | 705.6M | 775.6M | 837.9M |
| Gross Profit | 779.5M | 757.6M | 696.5M | 736.1M | 735.1M |
| Operating Expenses | |||||
| R&D Expense | 68.8M | 65.0M | 61.8M | 64.6M | 87.0M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 127.9M | 127.0M | 118.9M | 118.8M | 148.9M |
| Selling & Marketing Expense | 270.4M | 267.4M | 247.8M | 228.0M | 252.1M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 468.7M | 458.9M | 404.6M | 409.6M | 495.3M |
| Cost and Expenses | 1.2B | 1.2B | 1.1B | 1.2B | 1.3B |
| Operating Income (EBIT) | 315.6M | 304.3M | 295.1M | 330.9M | 251.5M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 314.6M | 303.6M | 293.3M | 329.7M | 250.2M |
| Income Tax Expense | 42.5M | 41.8M | 45.9M | 53.2M | 37.9M |
| Bottom Line | |||||
| Net Income | 222.9M | 219.3M | 212.7M | 247.7M | 212.2M |
| Earnings from Cont. Ops | 272.1M | 261.8M | 247.5M | 276.5M | 212.3M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 222.9M | 219.3M | 212.7M | 247.7M | 212.2M |
| Per Share | |||||
| Basic EPS | CN¥0.27 | CN¥0.27 | CN¥0.26 | CN¥0.30 | CN¥0.26 |
| Diluted EPS | CN¥0.27 | CN¥0.27 | CN¥0.26 | CN¥0.30 | CN¥0.26 |
| Revenue Per Share | CN¥1.81 | CN¥1.78 | CN¥1.72 | CN¥1.86 | CN¥1.93 |
| Shares | |||||
| Basic Shares Outstanding | 814.2M | 818.8M | 814.1M | 814.3M | 814.1M |
| Diluted Shares Outstanding | 814.2M | 818.8M | 814.1M | 814.3M | 814.1M |
| Profitability Metrics | |||||
| EBITDA | — | 383.9M | 370.2M | 415.1M | 362.4M |
| D&A | — | 79.6M | 75.1M | 84.2M | 110.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026